MedTrace Logo

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

NCT03786419 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-05-13

No results posted yet for this study

Summary

This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy.

Conditions

  • Malignant Pleural Mesothelioma, Advanced
  • Malignant Pleural Mesothelioma, Unresectable

Interventions

DRUG

Atezolizumab

Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity

Sponsors & Collaborators

  • Health Pharma Professional Research

    lead OTHER

Principal Investigators

  • Jorge Arturo Alatorre Alexander, MD · Health Pharma Professional Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786419 on ClinicalTrials.gov